China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) Short Interest Down 64.6% in April

China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) saw a large drop in short interest in the month of April. As of April 30th, there was short interest totaling 3,264 shares, a drop of 64.6% from the April 15th total of 9,220 shares. Currently, 0.4% of the company’s stock are short sold. Based on an average daily volume of 20,765 shares, the days-to-cover ratio is presently 0.2 days.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the company. Wall Street Zen raised China SXT Pharmaceuticals to a “sell” rating in a report on Saturday, February 7th. Weiss Ratings raised China SXT Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a report on Friday, May 1st. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Sell”.

China SXT Pharmaceuticals Stock Down 1.3%

China SXT Pharmaceuticals stock traded down $0.02 during mid-day trading on Friday, reaching $1.58. 5,532 shares of the stock traded hands, compared to its average volume of 216,270. China SXT Pharmaceuticals has a 12-month low of $1.25 and a 12-month high of $1,046.99. The business’s 50-day moving average is $1.86 and its 200-day moving average is $85.84.

Institutional Trading of China SXT Pharmaceuticals

Several hedge funds have recently bought and sold shares of SXTC. XTX Topco Ltd bought a new stake in China SXT Pharmaceuticals during the fourth quarter valued at about $36,000. Virtu Financial LLC grew its holdings in China SXT Pharmaceuticals by 107.5% during the third quarter. Virtu Financial LLC now owns 28,983 shares of the company’s stock valued at $46,000 after purchasing an additional 15,013 shares during the period. Finally, Citadel Advisors LLC bought a new stake in China SXT Pharmaceuticals during the third quarter valued at about $78,000. Institutional investors own 5.02% of the company’s stock.

About China SXT Pharmaceuticals

China SXT Pharmaceuticals Inc (NASDAQ: SXTC) is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of peptide-based therapeutics. The company’s pipeline centers on novel treatments targeting oncology, endocrine and metabolic disorders. By leveraging proprietary peptide synthesis and formulation technologies, China SXT aims to advance next-generation biologics that address unmet medical needs in both domestic and international markets.

The company’s core product candidates include long-acting peptide hormones and peptide-drug conjugates designed to improve patient compliance and therapeutic efficacy.